• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.美罗培南-巴坦治疗严重革兰氏阴性菌感染患者临床结局与安全性的真实世界多中心分析
Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.
2
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.美罗培南-法硼巴坦对 2014 年期间全球收集的当代革兰氏阴性分离株进行了测试，包括耐碳青霉烯类、产 KPC、多药耐药和广泛耐药的肠杆菌科。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00567-17. Print 2017 Sep.
3
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and .美罗培南-巴坦治疗革兰氏阴性菌感染（包括耐碳青霉烯菌感染）的真实世界多中心经验
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371. eCollection 2021 Aug.
4
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.亚胺培南-西司他丁钠和美罗培南-法硼巴坦：两种新型碳青霉烯-β-内酰胺酶抑制剂复方制剂。
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
5
Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.美罗培南-法硼巴坦治疗成人复杂性尿路感染和其他侵袭性感染。
Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5.
6
Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.美罗培南-法硼巴坦：一种碳青霉烯类和β-内酰胺酶抑制剂，对碳青霉烯类耐药的肠杆菌科具有活性。
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19.
7
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.美罗培南-巴坦与最佳可用疗法治疗耐碳青霉烯类肠杆菌科细菌感染患者的疗效和安全性：TANGO II随机临床试验
Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.
8
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.2015 年美罗培南/沃诺拉赞监测项目中耐碳青霉烯肠杆菌科细菌的美罗培南/沃诺拉赞体外活性和碳青霉烯耐药机制特征。
Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.
9
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.美罗培南-法硼巴坦对产 KPC 碳青霉烯酶耐药肠杆菌科细菌感染小鼠模型的作用。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01446-17. Print 2018 Jan.
10
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.美罗培南-法硼巴坦：抵抗革兰氏阴性菌感染的新武器。
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.

引用本文的文献

1
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.新型β-内酰胺/β-内酰胺酶抑制剂联合用药的临床疗效、安全性及药代动力学：一项系统评价
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
2
Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.美罗培南-巴坦治疗耐碳青霉烯类肠杆菌科细菌感染：临床实践证据的叙述性综述
Infect Dis Ther. 2025 May;14(5):973-989. doi: 10.1007/s40121-025-01146-x. Epub 2025 Apr 12.
3
Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.骨与关节感染中耐多药革兰氏阴性病原体的抗菌治疗选择
Pathogens. 2025 Feb 1;14(2):130. doi: 10.3390/pathogens14020130.
4
Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.评估两种梯度扩散试验以确定对氨曲南和头孢他啶-阿维巴坦联合用药的敏感性。
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0173624. doi: 10.1128/aac.01736-24. Epub 2025 Feb 7.
5
National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for .美罗培南-巴坦姆同情用药全国队列研究：对……而言，其效果并不优于美罗培南
Antibiotics (Basel). 2024 Dec 1;13(12):1152. doi: 10.3390/antibiotics13121152.
6
Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.标题：美罗培南-法硼巴坦与最佳现有治疗方案治疗耐碳青霉烯类肠杆菌科细菌感染患者的临床疗效和安全性的系统评价和荟萃分析。
Int J Mol Sci. 2024 Sep 4;25(17):9574. doi: 10.3390/ijms25179574.
7
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.用于革兰氏阴性医院获得性肺炎的新型抗生素
Antibiotics (Basel). 2024 Jul 5;13(7):629. doi: 10.3390/antibiotics13070629.
8
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.美罗培南-巴坦治疗KPC-Kp感染患者的死亡率结局及预测因素：一项观察性多中心研究
Open Forum Infect Dis. 2024 May 8;11(6):ofae273. doi: 10.1093/ofid/ofae273. eCollection 2024 Jun.
9
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.腹腔内感染的管理：意大利抗菌药物优化使用理事会的建议。
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
10
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.美罗培南/瓦博巴坦：β-内酰胺/β-内酰胺酶抑制剂组合，根除多重耐药性的未来。
Antibiotics (Basel). 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612.

本文引用的文献

1
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.美罗培南-法硼巴坦治疗碳青霉烯类耐药肠杆菌科感染的早期经验。
Clin Infect Dis. 2020 Jul 27;71(3):667-671. doi: 10.1093/cid/ciz1131.
2
A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?一项系统评价：迟发性恰当治疗与住院治疗感染肺炎克雷伯菌或大肠埃希菌患者死亡率之间的关联：多长时间算过长？
BMC Infect Dis. 2018 Dec 5;18(1):625. doi: 10.1186/s12879-018-3524-8.
3
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.美罗培南-巴坦与最佳可用疗法治疗耐碳青霉烯类肠杆菌科细菌感染患者的疗效和安全性：TANGO II随机临床试验
Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.
4
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.美罗培南-维巴坦与哌拉西林-他唑巴坦治疗复杂性尿路感染的临床疗效和微生物清除率：TANGO I 随机临床试验。
JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.
5
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.美罗培南和瓦博巴坦：加强对抗碳青霉烯类耐药肠杆菌科细菌的战斗。
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
6
Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department.急诊科严重脓毒症和脓毒性休克早期管理的感染病团队。
Clin Infect Dis. 2017 Oct 15;65(8):1253-1259. doi: 10.1093/cid/cix548.
7
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.革兰氏阴性菌感染：抗菌药物耐药性领导小组的研究重点、成果及未来方向
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S30-S35. doi: 10.1093/cid/ciw829.
8
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.产碳青霉烯酶肠杆菌科血流感染患者死亡率的预测模型。
Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024.
9
Impact of Source Control in Patients With Severe Sepsis and Septic Shock.严重脓毒症和感染性休克患者的源头控制的影响。
Crit Care Med. 2017 Jan;45(1):11-19. doi: 10.1097/CCM.0000000000002011.
10
Treating infections caused by carbapenemase-producing Enterobacteriaceae.治疗产碳青霉烯酶肠杆菌科细菌感染。
Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12.

美罗培南-巴坦治疗严重革兰氏阴性菌感染患者临床结局与安全性的真实世界多中心分析

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.

作者信息

Alosaimy Sara, Jorgensen Sarah C J, Lagnf Abdalhamid M, Melvin Sarah, Mynatt Ryan P, Carlson Travis J, Garey Kevin W, Allen David, Venugopalan Veena, Veve Michael, Athans Vasilios, Saw Stephen, Yost Christine N, Davis Susan L, Rybak Michael J

机构信息

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.

出版信息

Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.

DOI:10.1093/ofid/ofaa051
PMID:32161775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7060146/
Abstract

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

摘要

40例患者接受美罗培南-巴坦（MEV）治疗严重革兰氏阴性菌（GNB）感染。耐碳青霉烯类（CRE）占所有GNB感染的80.0%。70.0%的患者临床治疗成功。30天的死亡率和复发率分别为7.5%和12.5%。1例患者可能因MEV出现皮疹皮疹皮疹。